AZD2516 + Placebo

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Part A Healthy Young Males and Non-fertile Female Volunteers Aged 20 to 45 Years.

Conditions

Part A Healthy Young Males and Non-fertile Female Volunteers Aged 20 to 45 Years., Part B Healthy Young Males and Non-fertile Female Volunteers Aged 20 to 45 and Elderly Volunteers Aged 60 to 80

Trial Timeline

Jun 1, 2010 → Jul 1, 2010

NCT ID

NCT01148095

About AZD2516 + Placebo

AZD2516 + Placebo is a phase 1 stage product being developed by AstraZeneca for Part A Healthy Young Males and Non-fertile Female Volunteers Aged 20 to 45 Years.. The current trial status is completed. This product is registered under clinical trial identifier NCT01148095. Target conditions include Part A Healthy Young Males and Non-fertile Female Volunteers Aged 20 to 45 Years., Part B Healthy Young Males and Non-fertile Female Volunteers Aged 20 to 45 and Elderly Volunteers Aged 60 to 80.

What happened to similar drugs?

20 of 20 similar drugs in Part A Healthy Young Males and Non-fertile Female Volunteers Aged 20 to 45 Years. were approved

Approved (20) Terminated (4) Active (0)

✅Perampanel + PlaceboEisaiApproved

✅Adjunctive Zonisamide + Replacement with ZonisamideEisaiApproved

✅PerampanelEisaiApproved

✅Eslicarbazepine acetate + Eslicarbazepine AcetateSumitomo PharmaApproved

✅DoravirineMerckApproved

✅Azithromycin + Azithromycin and amoxicillin + PlaceboMerckApproved

✅OxcarbazepineNovartisApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01148095	Phase 1	Completed	Jun 1, 2010	Jul 1, 2010	Part A Healthy Young Males and Non-fertile Female Volunteers Aged 20 to 45 Years.
NCT00972049	Phase 1	Completed	Sep 1, 2009	Dec 1, 2009	Healthy
NCT00754715	Phase 1	Completed	Sep 1, 2008	Dec 1, 2008	Healthy

Competing Products

20 competing products in Part A Healthy Young Males and Non-fertile Female Volunteers Aged 20 to 45 Years.

See all competitors

Product	Company	Stage	Hype Score
Use of Wearable Digital Sensors After mRNA Vaccination in Adults	Moderna	Preclinical	0
mRNA-0184	Moderna	Phase 1	0
mRNA-0184	Moderna	Phase 1	0
LY2409021	Eli Lilly	Phase 1	29
Ixekizumab	Celltrion	Phase 1	33
YH35995 + Placebo	Yuhan	Phase 1	36
Trastuzumab deruxtecan	Daiichi Sankyo	Phase 2	42
ASP8731 + ASP8731 Matching Placebo	Astellas Pharma	Phase 1	21
Ensitrelvir	Shionogi	Phase 1	29
Rosuvastatin + BPN14770	Shionogi	Phase 1	29
S-892216-LAI + Placebo	Shionogi	Phase 1	36
S-740792 Suspension + Midazolam + Placebo + S-740792 Tablet	Shionogi	Phase 1	29
E6130 + Placebo	Eisai	Phase 1	21
E2007	Eisai	Phase 3	40
E6130 + Placebo	Eisai	Phase 1	29
E7386	Eisai	Phase 1	29
Perampanel	Eisai	Pre-clinical	26
perampanel + perampanel	Eisai	Phase 1	29
perampanel + perampanel + perampanel + Placebo	Eisai	Phase 3	40
Perampanel + Placebo	Eisai	Approved	35